- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05721937
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
CIBINQO™ Pregnancy Registry: An Observational Study of the Safety of Abrocitinib Exposure in Pregnant Women and Their Offspring
The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring.
The study is seeking participants who:
- Are currently or recently pregnant
- Receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy OR have a diagnosis of moderate-to-severe atopic dermatitis
All participants in this study will receive treatment according to routine care, as this is an observational study. The exposed group will consist of pregnant women exposed to abrocitinib during pregnancy. The unexposed group will consistent of pregnant women with moderate-to-severe atopic dermatitis who are not exposed to abrocitinib during pregnancy.
The study will compare the experiences of pregnant women receiving abrocitinib to pregnant women who do not. This will help us determine if abrocitinib is safe during pregnancy.
Participants will take part in this study until their infant is 12 months of age. During this time, the participant's care will be managed no differently than if she was not taking part in this study. Data will be collected through a virtual research coordinating center at enrollment, the end of the second trimester, and pregnancy outcome (live birth or fetal loss). For live-born infants, data on the infants will be collected at 4 and 12 months of age. No additional visits beyond routine care will be required.
Study Overview
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Pfizer CT.gov Call Center
- Phone Number: 1-800-718-1021
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
Study Locations
-
-
New York
-
New York, New York, United States, 10001
- Recruiting
- Pfizer
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women of any age who are currently or recently pregnant (recently pregnant defined as enrollment within 1 year of pregnancy outcome)
- Consent to participate in this study and evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
- Authorization for her healthcare provider(s) to provide data to the registry
- Must receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy (within 1 day prior to the date of conception) OR have a diagnosis of moderate-to-severe atopic dermatitis at any time prior to pregnancy outcome.
Exclusion Criteria:
- Participants will be excluded from the registry if they do not meet the inclusion criteria listed above.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Exposed to CIBINQO during pregnancy
Received at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy (within 1 day prior to the date of conception).
|
taken by mouth
|
Unexposed to CIBINQO during pregnancy
Diagnosed with moderate-to-severe atopic dermatitis, but not exposed to CIBINQO during pregnancy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of live birth children with major congenital malformations
Time Frame: Enrollment until 12 months after delivery
|
An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention.
|
Enrollment until 12 months after delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of participants with children with minor congenital malformations
Time Frame: Enrollment until 12 months after delivery
|
An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual.
|
Enrollment until 12 months after delivery
|
Percent of participants with spontaneous abortion
Time Frame: Enrollment until end of pregnancy (up to 20 gestational weeks)
|
An involuntary fetal loss or the expulsion of the products of conception occurring at <20 gestational weeks.
|
Enrollment until end of pregnancy (up to 20 gestational weeks)
|
Percent of participants with stillbirths
Time Frame: Enrollment until end of pregnancy (up to 9 months)
|
An involuntary fetal loss occurring at ≥20 gestational weeks or, if gestational age is unknown, a fetus weighing ≥350 g.
|
Enrollment until end of pregnancy (up to 9 months)
|
Percentage of participants with an elective termination
Time Frame: Enrollment until end of pregnancy (up to 9 months)
|
A voluntary fetal loss or interruption of pregnancy that occurs for any reason, including but not limited to for the preservation of maternal health or due to fetal abnormalities
|
Enrollment until end of pregnancy (up to 9 months)
|
Percent of participants with preterm birth
Time Frame: Enrollment until 12 months after delivery
|
A live birth occurring at <37 gestational weeks.
|
Enrollment until 12 months after delivery
|
Percent of participants with children born small for gestational age
Time Frame: Enrollment until 12 months after delivery
|
Birthweight <10th percentile for sex and gestational age using standard growth charts for full and preterm live born infants.
|
Enrollment until 12 months after delivery
|
Percentage of participants with children with postnatal growth deficiency
Time Frame: Enrollment until 12 months after delivery
|
Weight, length, or head circumference in <10th percentile for sex and chronological age using standard growth charts
|
Enrollment until 12 months after delivery
|
Percent of participants with infant developmental delay
Time Frame: Enrollment until 12 months after delivery
|
Failure to achieve the developmental milestones for chronological age, as defined by the CDC.
|
Enrollment until 12 months after delivery
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B7451095
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on Abrocitinib
-
PfizerActive, not recruitingAtopic DermatitisIndia
-
Innovaderm Research Inc.Not yet recruiting
-
PfizerActive, not recruitingDermatitis, AtopicChina, United States, Spain, Taiwan, Germany, Australia, Canada, Hungary, Korea, Republic of, Poland, Serbia, Bulgaria, Czechia, Japan, Latvia, United Kingdom, Belgium, Israel, Italy, Finland, Mexico, Romania, Slovakia, Argentina, Brazil, Chil... and more
-
PfizerAvailableAtopic DermatitisTaiwan, United States, Australia, Austria, Belgium, Canada, Greece, Mexico, Netherlands, Russian Federation, Spain, Switzerland
-
William DamskyYale University; PfizerActive, not recruiting
-
PfizerIn Expanded Access, treating physicians are the SponsorAvailableSevere Uncontrolled Atopic Dermatitis
-
National Institute of Diabetes and Digestive and...PfizerRecruitingDiabetes Mellitus, Type 1United States
-
PfizerCompletedAtopic DermatitisSpain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy